Skip to main content
. 2024 Aug 20;37:13220. doi: 10.3389/ti.2024.13220

TABLE 3.

Clinical differences from the comparison of KTRs who developed cancer (CA+) and KTRs without cancer diagnosis (CA-).

Clinical variables CA- (n = 753) CA+ (n = 177) p-value
Sex - n (%) Male patients
Female patients
426 (79.3%)
327 (83.2%)
111 (20.7%)
66 (16.8%)
0.08
Transplant donor - n (%) Deceased
Living
620 (79.9%)
131 (86.2%)
156 (20.1%)
21 (13.8%)
0.04
Age at KTx - years 47.5 ± 13 54.6 ± 10.6 <0.001
Dialysis type - n (%) HD
PD
No
522 (80.6%)
139 (76.8%)
68 (87.2%)
125 (19.4%)
42 (23.2%)
10 (12.8%)
0.17
Dialysis vintage - months 51.2 ± 49 57.8 ± 57.1 0.06
Diabetes pre-KTx - n (%) Yes
No
44 (81.5%)
684 (80.5%)
10 (18.5%)
166 (19.5%)
0.51
History of HCV infection - n (%) Yes
No
26 (70.3%)
422 (74.7%)
11 (29.7%)
143 (25.3%)
0.33
Steroids pre-KTx - n (%) Yes
No
269 (81%)
417 (80.8%)
63 (19%)
99 (19.2%)
0.50
Causes of ESRD – n (%) CN
GN
HUS
ADPKD
Vasculitis
PN/NI
Other
Undetermined
145 (79.7%)
154 (80.6%)
16 (94.1%)
118 (73.3%)
23 (67.6%)
91 (86.7%)
107 (84.9%)
99 (86.8%)
37 (20.3%)
37 (19.4%)
1 (5.9%)
43 (26.7%)
11 (32.4%)
14 (13.3%)
19 (15.1%)
15 (13.2%)
0.011

HD, hemodialysis; PD, peritoneal dialysis; CN, chronic nephropathy; GN, glomerulonephritis; HUS, hemolytic uremic syndrome; ADPDK, autosomal dominant polycystic kidney disease; PN/NI, pyelonephritis and interstitial nephritis.

Bold value indicates the statistic significance (p < 0.05).